Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140060 | 1.00 | RAB9A (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL947177 | 0.80 | — | — | |
| Methyl Alcohol SCHEMBL28478479 | 0.79 | NPC1 (0.89) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL11105985 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL10801184 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL2989454 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL6160201 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL256048 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL31124655 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL6556168 | 0.78 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10248594-A | — | — | None | — | — | JP | disclosed |
| CN-108727179-B | Synthetic method of alpha-allyl substituted alpha, beta-unsaturated ketone, ester or nitrile compound | 信阳师范学院 | 2021-04-30 | — | — | CN | disclosed |
| CN-103827088-B | It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors | 奇斯药制品公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-106946848-A | It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors | 奇斯药制品公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-106946848-A | It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors | 奇斯药制品公司 | 2017-07-14 | — | — | CN | disclosed |
| WO-2010009275-A1 | METHODS OF TREATING INFLAMMATION | INTEGRITAS PHARMA, INC (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-1416926-A4 | ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE | SMITH JEFFREY B (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | US | disclosed |
| EP-1416926-A2 | ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE | Smith, Jeffrey B. (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2002098339-A2 | ZINC CONTAINING COMPOSITIONS FOR ANTI-VIRAL USE | SMITH JEFFREY B (US) | 2002-12-12 | — | — | WO | disclosed |
| JP-H10248594-A | ASYMMETRIC RESOLUTION OF PYRIDYLALCOHOLS | UBE IND LTD | 1998-09-22 | — | — | JP | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| US-5283245-A | Antiinflammatory agent, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-01 | — | — | US | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
| EP-0381375-B1 | HETEROCYCLIC DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-11 | — | — | EP | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| EP-0037254-B1 | ACETIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND COMPOSITION CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1984-07-25 | — | — | EP | disclosed |
| US-4356186-A | ANTIINFLAMMATORY, ANALGESIC, AND ANTIPYRETIC, AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1982-10-26 | — | — | US | disclosed |
| EP-0037254-A1 | Acetic acid derivatives, process for the preparation thereof and composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | ABCB1, UGT2B17, CYP7B1 | RAB9A 1851/4885NPC1 104/4885MEN1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.